Congresswoman Demands Answers from Trump Administration on Cannabis Policy
Congressional Cannabis Caucus Co-Chair Rep. Dina Titus (D-NV) is demanding answers from the Trump administration regarding its decision to rescind Biden-era enforcement guidance on cannabis. Titus claims that the move is a “step backward for commonsense cannabis policy reform.”
Meanwhile, Rep. Troy Carter (D-LA) and other Democratic lawmakers have filed a congressional resolution calling for equity-focused marijuana policies and urging President Donald Trump to advocate for global cannabis reform at the United Nations.
In other cannabis-related news, Sens. Cory Booker (D-NJ) and Rand Paul (R-KY), along with Reps. Madeleine Dean (D-PA) and Nancy Mace (R-SC), have filed legislation to allow doctors to administer psychedelics and other Schedule I substances to patients with life-threatening conditions in accordance with the Right to Try law.
Additionally, Rep. Warren Davidson (R-OH) has asked federal financial regulators about the cannabis industry’s banking access issues, stating that “nearly every state, whether you like it or not, has made some form of marijuana lawful in those states, and we haven’t synced up at the federal level.”
Missouri lawmakers have pre-filed several marijuana, hemp, and psychedelics bills for the 2026 session, including measures to release people in prison for cannabis, allow medical marijuana use on college campuses, and facilitate psilocybin therapy.
A new analysis from NORML shows that researchers published more than 37,000 scientific papers on marijuana over the past 10 years, including over 4,000 in 2025 alone. The Trump administration is currently considering a cannabis rescheduling proposal.
In other news, the Nebraska Supreme Court heard oral arguments in a Republican former state senator’s lawsuit seeking to overturn the medical cannabis legalization law approved by voters last year.
The Department of Veterans Affairs has posted a brief about a study indicating that CBD may harm kidneys. The International Trade Administration has approved an application for duty-free entry into the U.S. of a scientific instrument intended to investigate the effects of THC and CBD on neurodevelopment.
